This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


  • 00
  • 00
  • 00
  • 00
Delivered as a Hybrid Event from December 12 - 16, 2021
Live In-Person Experience Delivered December 12 - 16 2021Marriott Marquis San Diego

Charles Theuer, M.D., Ph.D.
Director, President and CEO at Tracon Pharmaceuticals


Dr. Theuer has been CEO and President and a Director of TRACON Pharmaceuticals (NASDAQ: TCON) since 2006. Prior thereto, from October 2004 to July 2006, Dr. Theuer was Chief Medical Officer at TargeGen Inc., where he initiated the development of small molecule kinase inhibitors in oncology (including Inrebic® (fedratinib), a JAK2 inhibitor approved for myelofibrosis), ophthalmology and cardiovascular disease.  From October 2003 to October 2004, Dr. Theuer was the Director, Clinical Oncology at Pfizer, where he led the clinical development of Sutent® (sunitinib) in kidney cancer; Sutent® was approved by the U.S. Food and Drug Administration in January 2006 for treating advanced kidney cancer.  Prior thereto, Dr. Theuer held senior positions at IDEC Pharmaceuticals, from June 2002 to October 2003, and the National Cancer Institute developing other agents, including small molecules and monoclonal antibody therapies.  Dr. Theuer holds a B.S. degree from the Massachusetts Institute of Technology, an M.D. degree from the University of California, San Francisco and a Ph.D. degree from the University of California, Irvine.  He completed a residency in general surgery at Harbor-UCLA Medical Center and was Board Certified in general surgery in 1997.  Dr. Theuer held academic positions at the National Cancer Institute and at the University of California, Irvine, where he was a member of the Division of Surgical Oncology and Department of Medicine.  His previous research involved immunotoxin and cancer vaccine development, translational work in cancer patients, as well as gastro-intestinal cancer epidemiology.  He serves as a Board member of TRACON Pharmaceuticals, 4D Molecular Therapeutics (NASDAQ: FDMT), and Oncternal Therapeutics (NASDAQ: ONCT).

Agenda Sessions

  • Envafolimab: A Single Domain PD-L1 Antibody Given by Rapid Subcutaneous Injection That Is Being Studied in Pivotal Trials in the US and China